Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
Glanzmann’s Research Foundation shared a post on LinkedIn:
“More than four years ago, we visited David Wilcox and his team at the Medical College of Wisconsin, where they have spent decades advancing a potential gene therapy cure for GlanzmannThrombasthenia.
Today, we are closer than ever to clinical trials, and we’ll soon be returning to the lab to see firsthand how much progress has been made.
The science is there. The expertise is there.
The biggest barrier to this research reaching patients is funding.
What makes the us so unique as a non-profit in the rare bleeding disorders space is that all donations directly support research to find a cure.
Every donation helps move this promising therapy one step closer to clinical trials.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering